Skip To Main Content
Rebecca CS Edgar on Muck Rack

Rebecca CS Edgar

As seen in: BioRxiv, eLife
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rebecca CS

Contact Rebecca CS, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy

|
By Carlo Giannangelo, Matthew Challis, Ghizal Siddiqui, Rebecca CS Edgar
| eLife
eLife assessment The manuscript makes an important contribution to antimalarial drug discovery, utilizing diverse systems biology methodologies. It focuses on an improved M1 metalloprotease inhibitor and provides compelling evidence for the utility of chemoproteomics in pinpointing PfA-M1 targeting. Additionally, metabolomic analysis reveals specific alterations in the final steps of hemoglobin breakdown.
Open in Who Shared Issue with article?

Taste of Oakville is Back and Serving up Oakville’s Best Dishes this Winter!

|
By Rebecca CS Edgar
| visitoakville.com
January 24, 2024 NEWS RELEASE OAKVILLE – Oakville’s culinary scene is set to dazzle taste buds once again as the highly anticipated Taste of Oakville returns for its 2024 edition from February 15 – March 10. This year, more than thirty-five restaurants from across town will showcase an array of mouth-watering dishes via multi-course prix fixe lunch and dinner menus. Prices range from $20-$35 for lunch and $30-$65 for dinner.
Open in Who Shared Issue with article?

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.

|
By Rebecca CS Edgar, Ghizal Siddiqui, Tess R Malcolm, Sandra Duffy
| BioRxiv
Abstract To combat the global burden of malaria, development of new drugs to replace or complement current therapies are urgently required. As drug resistance to existing treatments and clinical failures continue to rise, compounds targeting multiple life cycle stages and species need to be developed as a high priority.
Open in Who Shared Issue with article?
See all 15 articles